# V50 T/B-Readable Monitoring Source Search Results

Status: future search/navigation only. This file records a narrow source-search
pass for the T/B-readable early IFN/APC/STAT1 monitoring-state row. It does not
add external records, assert convergence, or change any grounded finding.

Search date: `2026-06-28`.

## Search Queries Run

| route | query |
|---|---|
| web / literature | `"multiple sclerosis" "treatment response" "STAT1" "B cells" transcriptome` |
| web / literature | `"multiple sclerosis" "interferon" "HLA" "B cells" "treatment response"` |
| web / literature | `"multiple sclerosis" "single-cell" "treatment response" "interferon" "B cell"` |
| web / literature | `"multiple sclerosis" "early treatment" "PBMC" "STAT1"` |

## Candidate Hits

| candidate | source | overlap | decision |
|---|---|---|---|
| Interferon-beta corrects gene dysregulation in MS | https://pmc.ncbi.nlm.nih.gov/articles/PMC6945282/ | IFN-beta treatment biology and gene-expression context; not a T/B-readable early monitoring rule with response labels. | partial context only; do not create convergence row. |
| Cladribine single-cell memory B-cell reduction correlated with treatment response | https://pmc.ncbi.nlm.nih.gov/articles/PMC10710756/ | Single-cell B-cell treatment-response context; not the project's IFN/APC/STAT1 early state and not DMF. | partial context only; possible future B-cell treatment-response record if needed. |
| B-cell activity predicts response to glatiramer acetate or interferon beta-1a | https://www.neurology.org/doi/10.1212/NXI.0000000000000980 | B-cell activity and treatment response; likely relevant to compartment-readability, but not a same-definition IFN/APC/STAT1 module test. | partial context only; no relationship row without source review. |
| Altered immune phenotypes and HLA-DQB1 variation in MS patients failing interferon beta treatment | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.628375/full | HLA-linked immune phenotype and IFN-beta failure context; not transcriptomic T/B/APC monitoring under project definitions. | partial context only; no convergence row. |
| DMF-related immune and transcriptional signature | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1209923/full | DMF response transcriptomic/immunophenotype context already represented by the V50 GSE235357 record. | already covered as validation-context, not a same-definition T/B-readable rule. |

## Result

No same-definition external source was found in this pass.

The search improves routing: future T/B-readable monitoring-source intake should
prioritize sources with all of the following fields:

1. MS treatment or relapse-response setting.
2. T/B/APC compartment-readable expression or single-cell data.
3. IFN/APC/STAT1/HLA-II readouts or scoreable gene expression.
4. Early timepoint or paired pre/post treatment design.
5. Response/state label.

## Decision

Keep the T/B-readable early IFN/APC/STAT1 monitoring-state row as
insufficiently externally covered. The current partial hits can guide future
source intake, but none should be used as external corroboration for the project
state.
